Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
May 18, 2018 • 8:00 AM EDT
Ligand Prices Offering of $650 Million of Convertible Senior Notes
May 16, 2018 • 4:51 PM EDT
Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes
May 11, 2018 • 9:00 AM EDT
Ligand to Participate in Upcoming Investor Conferences
May 24, 2018 • 11:45am EDT
New York, NY
See all events
May 8, 2018 • 4:30pm EDT
Mar 13, 2018 • 8:30am EDT
May 30, 2018
Jun 6, 2018 • 8:00am EDT
Jun 14, 2018 • 8:30am PDT
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121
CASI Pharmaceuticals $CASI announces Q1 business updates; indicates preparations for EVOMELA commercial launch in C… https://t.co/MNFwm2ytsX
MEI Pharma announces presentation of ME-344 clinical data at American Society of Clinical Oncology meeting #ASCO18 https://t.co/5UDxuAkVZq
CStone raises $260 million in Series B financing to advance novel cancer therapies, including OmniAb-derived CS1001 https://t.co/a6hro3Ahcx